LAIF and ABRACE
Scientific research project conducted in partnership with the Associação Brasileira de Apoio Cannabis Esperança (ABRACE) in the theme: cannabinoid ligands vs. chronic pain.
link: https://abraceesperanca.org.br/home/
Lista de referências bibliográficas completas
BONFÁ, L.; VINAGRE, R. C. O.; FIGUEIREDO, N. V. Uso de canabinóides na dor crônica e em cuidados paliativos. Revista Brasileira de Anestesiologia, 58, 3, 267-279, 2008.
BOUCHET, C. A.; INGRAM, S. L. Cannabinoids in the descending pain modulatory circuit: Role in inflammation. Pharmacology & Therapeutics, 107495, 1-66, 2020.
BOYAJI, S. et al. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Current Pain and Headache Reports, 24, 2, 1-6, 24, 2020.
CAMPOS, A. C. et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research, 112, 119-127, 2016.
CHAGAS, M. H. N. et al. Neuroimaging of major depression in Parkinson’s disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. Journal of Psychiatric Research, 90, 40-45, 2017.
DAVIS, K. D. et al. Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations. Nature Reviews Neurology, 13, 10, 624–638, 2017.
DONVITO, G. et al. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology, 43, 1, 52-79, 2017.
DRUMMER, O. H.; ODELL, M. S. The forensic pharmacology of drugs of abuse. London: Arnold, 2001.
DUBOIS, M.; GALLAGHER, R.; LIPPE, P. Pain medicine position paper. Pain Medicine, 10, 6, 972–1001, 2009.
ELLER-SMITH, O. C.; NICOL, A. L.; CHRISTIANSON, J. A. Potential mechanisms underlying centralized pain and emerging therapeutic interventions. Frontiers in Cellular Neuroscience, 12, 1-35, 2018.
GMUCA, S.; SHERRY, D. D. Fibromyalgia: treating pain in the juvenile patient. Pediatric Drugs, 19, 4, 325-338, 2017.
GROTENHERMEN, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42, 4, 327-360, 2003.
GUINDON, J.; HOHMANN, A. The endocannabinoid system and pain. CNS & Neurological Disorders – Drug Targets, 8, 6, 403-421, 2009.
HARPER, D. E. et al. Resting functional connectivity of the periaqueductal gray is associated with normal inhibition and pathological facilitation in conditioned pain modulation. The Journal of Pain, 19, 6, 635-650, 2018.
HOFFMAN, A. S. Stimuli-responsive polymers: biomedical applications and challenges for clinical translation. Advanced Drug Delivery Reviews, 65, 1, 10-16, 2013.
JENSEN, K. B. et al. Patients with fibromyalgia display less functional connectivity in the brain’s pain inhibitory network. Molecular Pain, 8, 1744-8069, 2012.
KABANOV, A. V. et al. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. The Journal of Controlled Release, 82, 2-3, 189-212, 2002.
KATAOKA, K. et al. Block copolymer micelles for drug delivery: design, characterization and biological significance. Advanced Drug Delivery Reviews, 47, 1, 113-131, 2001.
KAUR, A. et al. Ameliorative effect of imperatorin in chemically induced fibromyalgia: Role of NMDA/NFkB mediated downstream signalling. Biochemical Pharmacology, 166, 56-69, 2019.
KLEIN, C. P. et al. Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology, 86, 57-66, 2014.
KUNER, R.; FLOR, H. Structural plasticity and reorganisation in chronic pain. Nature Reviews Neuroscience, 18, 1, 20–30, 2016.
LESNAK, J.; SLUKA, K. A. Chronic non-inflammatory muscle pain: central and peripheral mediators. Current Opinion in Physiology, 11, 67-74, 2019.
LIU, D. et al. Biosorption of acid blue 25 by unmodified and CPC-modified biomass of pPenicillium YW01: kinetic study, equilibrium isotherm and FTIR analysis. Colloid Surface B, 85, 2, 262-269, 2011.
LYNCH, M. E.; CAMPBELL, F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 5, 735-744, 2011.
MEASE, P. J. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. The American Journal of Medicine, 122, 12, S44–S55, 2009.
NAGAKURA, Y. et al. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain, 146, 1, 26-33, 2009.
NAPADOW, V. et al. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis & Rheumatism, 62, 8, 2545-2555, 2010.
NASCIMENTO, G. C. et al. Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson’s disease. Neuropharmacology, 163, 1-11, 2020.
PARK, E. K. et al. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials, 26, 9, 1053-1061, 2005.
PERL, E. R. Ideas about pain, a historical view. Nature Reviews Neuroscience, 8, 71–80, 2007.
PITTELLA, F. et al. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials, 32, 11, 3106-3114, 2011.
PITTELLA, F. et al. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles. The Journal of Controlled Release, 161, 3, 868-874, 2012.
REZENDE, R. M. et al. Does aerobic exercise associated with tryptophan supplementation attenuates hyperalgesia and inflammation in female rats with experimental fibromyalgia? Plos One, 14, 2, 1-14, 2019.
RUSSO, E. B. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1, 1, 154-165, 2016.
RUSSO, E. B. Cannabidiol claims and misconceptions. Trends in Pharmacological Sciences, 38, 3, 198–201, 2017.
SARZI-PUTTINI, P. et al. Cannabinoids in the treatment of rheumatic diseases: Pros and cons. Autoimmunity Reviews, 18, 12, 1-7, 2019.
SLUKA, K. A.; CLAUW, D. J. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience, 338, 114–129, 2016.
SOSA-REINA, M. D. et al. Effectiveness of therapeutic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomized clinical trials. Biomed Research International, 2017, 1-14, 2017.
STAUD, R.; RODRIGUEZ, M. E. Mechanisms of disease: pain in fibromyalgia syndrome. Nature Clinical Practice Rheumatology. 2, 2, 90–98, 2006.
WOLFE, F. et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research, 62, 5, 600-610, 2010.
WOLFE, F. et al. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care & Research, 65, 5, 777-785, 2013.
WOLFE, F. et al. Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism, 46, 3, 319-329, 2016.
WOLFE, F. et al. All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia.. Seminars in Arthritis and Rheumatism, 16, S0049-0172(20)30028-7, 2020.
WONG, H. L. et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Advanced Drug Delivery Reviews, 59, 6, 491-504, 2007.
WONG, H.L. et al. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Advanced Drug Delivery Reviews, 62, 4-5, 503-517, 2010.